To examine whether plasma levels of coagulation factors , , , , , and , plasminogen, and -2 antiplasmin are associated with coronary heart disease (CHD) in a prospective case-cohort study. 
Introduction
Associations of several hemostatic factors, including fibrinogen, factors and , von Willebrand factor, tissue plasminogen activator antigen, and plasminogen activator inhibitor-1, with the risk of developing atherosclerotic diseases have been widely examined 1) . The Atherosclerosis Risk in Communities (ARIC) hemostatic factors were not examined in the ARIC study 2, 3) or other prospective studies of CHD occurrence. The a priori hypothesis was that these factors would be associated with increased risk of CHD, independently of classical risk factors.
Materials and Methods

Study Population
The ARIC Study comprised a community-based sample of 15,792 persons from 4 centers: Forsyth County, North Carolina; the city of Jackson, Mississippi; northwestern suburbs of Minneapolis, Minnesota; and Washington County, Maryland. Participants were 45 to 64 years of age during the baseline period (visit 1: 1987 to 1989 ). The study protocol was approved by each field center's institutional review board. After written informed consent was obtained, participants underwent a baseline clinical examination. Re-examinations were performed every 3 years, up to 9 years. Details of the ARIC study protocol have been described elsewhere 4) .
Incident CHD
Participants were followed for incident cardiovascular events through to the end of 1998 via annual telephone contact and surveillance of hospital and death records. For patients hospitalized with a potential myocardial infarction, trained abstractors recorded the presenting symptoms and related clinical information, including cardiac biomarkers, and photocopied up to three 12-lead ECGs for Minnesota coding. Outof-hospital deaths were investigated by means of death certificates and, in most cases, by an interview with one or more next of kin and a questionnaire filled out by the patient's physician. Coroner reports or autopsy reports, when available, were abstracted for use in validation. A CHD event was defined as a validated definite or probable hospitalized myocardial infarction, a definite CHD death, a silent myocardial infarction by electrocardiogram, or a coronary revascularization. The criteria for definite or probable myocardial infarction were based on combinations of chest pain symptoms, ECG changes, and cardiac biomarker levels 5, 6) . The criteria for definite fatal CHD were based on chest pain symptoms, history of CHD, underlying cause of death from the death certificate, and any other associated hospital information or medical history, including that from an ARIC clinic visit 6) . Stable or unstable angina pectoris was not recorded as a CHD event.
Case-Cohort Design
A case-cohort design was employed to study prospective associations between parameters measured in stored blood specimens at ARIC visit 2 (1990 − 1992) and subsequent cardiovascular events (CHD and stroke). Subjects were excluded if they had not participated in visit 2 examinations; if they had preexisting CHD or a transient ischemic attack/stroke before the visit 2 examination, or were missing information on CHD history. Due to small numbers, we also excluded subjects who were neither white nor African-American, or if they were African-American in the Washington County or Minneapolis field center (total n 3,014 excluded).
Incident cardiovascular events were identified from visit 2 through Dec 31st, 1998 (median follow-up 7.5 years). A total of 775 CHD events were identified during follow-up. A stratified cohort random sample (CRS) of 936 participants was selected from the eligible ARIC cohort (n 12,778). Stratification was done by age ( 55 or ≥ 55 years), sex and race (African-American or white). The number of subjects sampled in each stratum related to the number of incident CHD cases in that stratum from the visit 2 examination through to 1997. That is, in the two agestrata for white males the CRS numbers drawn were equal to the number of CHD cases in the strata, but in the other 6 strata the CRS numbers drawn were twice the number of CHD cases. Therefore some strata were oversampled, and thus we weighted each stratum of the CRS by the reciprocals of the sampling rates. The list of cases and the CRS were randomly sorted and split into two roughly equal parts. One part was selected to have hemostatic factors measured, and we successfully obtained values for 85%. In the end, 368 incident CHD events and 412 CRS subjects (including 25 CHD events in persons selected in the CRS) were included in this case-cohort study (Fig. 1) . Those included were not significantly different from those not included on major risk factors. Likewise, the CRS had largely identical risk factor levels as the whole ARIC cohort.
Measurements
Blood samples were collected at the visit 2 examination into sodium citrate anticoagulant tubes. Centrifuged plasma was stored at 70 in freezers until analyzed. After the selection of cases and the CRS, plasma vials were retrieved from the freezers. Coagulation and chromogenic assays were performed on an ACL9000 (Instrumentation Laboratory Co, Lexington, MA, USA) according to the manufacturer's instructions. Coagulation factors , , , , , and were measured using factor-deficient plasma and either a high sensitivity rabbit brain thromboplastin (IL Test PT-Fibrinogen HS) or aPTT reagent (rabbit brain phospholipids and silica; IL Test aPTT-C Activated Partial Thromboplastin Time). Plasminogen and -2 antiplasmin were measured with automated chromogenic assays (IL Test Plasminogen and IL Test plasmin inhibitor) using a synthetic chromogenic substrate, S-2403. Calibration Plasma (Assess Calibration Plasma, Instrumentation Laboratory, Barcelona, Spain) was used for the quantitation of coagulation and chromogenic tests, and standardized normal control plasma (Assess Normal Control, Instrumentation Laboratory) was used for quality control. To test the repeatability of measurements, we split 46 samples after blood drawing into pairs and processed, stored and analyzed them separately. The reliability coefficients between paired measurements were 0.75 for factor ; 0.68 for factor ; 0.82 for factor ; 0.68 for factor ; 0.90 for factor ; 0.89 for factor ; 0.86 for plasminogen; and 0.65 for -2 antiplasmin.
Sitting blood pressure at the visit 2 examination Case-cohort samples was measured three times using a random-zero sphygmomanometer after five minutes' rest and the mean of the last two measurements was used for analysis. Use of antihypertensive or cholesterol-lowering medications within the two weeks before the visit 2 interview was self-reported. Fasting plasma total, low-density and high-density lipoprotein cholesterol concentrations were measured by enzymatic methods. Diabetes mellitus was defined at baseline as a fasting glucose level ≥ 126 mg/dL, nonfasting glucose level ≥ 200 mg/dL, a history of physician-diagnosed diabetes, or use of diabetes medication. Cornell voltage was calculated with | S V3 | R aVL on the baseline ECG, and Cornell voltage 28 mV for men and 22 mV for women was considered to reflect left ventricular hypertrophy. Information on smoking and drinking status (current, ex-, or never smokers or drinkers), usual alcohol intake, menopausal status, and current use of salicylates (including salicylate combinations), coumarin and hormone replacement therapy, was derived from interviews. Body mass index (kg/m 2 ) was computed from weight in a scrub suit and standing height. Waist-hip ratio was calculated by the girth of the waist divided by the girth of the hips. Education level and sports index were derived from visit 1 interviews. Sports index represented sports during leisure time, based on the ARIC/Baecke questionnaire described elsewhere 7) . Pre-existing CHD at the visit 2 examination was defined by a self-reported prior physician's diagnosis of myocardial infarction or coronary revascularization, by prevalent myocardial infarction detected by 12-lead electrocardiography, or by an incident myocardial infarction between visits 1 and 2. Preexisting transient ischemic attack/stroke was defined by any self-reported physician's diagnosis of transient ischemic attack or stroke at visit 1 or by an incident stroke between visits 1 and 2.
Statistical Analysis
Unadjusted means or prevalences of baseline characteristics were computed for CHD cases and the CRS. For the CRS, mean values and prevalences were weighted according to the sampling fractions of sampling strata. We categorized subjects into quartiles of each hemostatic factor based on the distribution in the CRS. Hazard ratios (HR) and 95% confidence intervals (CI) of CHD in relation to quartiles were calculated using proportional hazard models, with Barlow's methods 8) to account for the case-cohort design. Trends across the quartiles were tested employing the median value for each quartile. Increments in HR and 95%CI for a 1-standard deviation difference in hemostatic factors were calculated by fitting the factors as standardized linear independent variables. Adjustments were made for age (continuous), sex, race (white or African-American), and other Framingham risk factors, i.e., systolic blood pressure (continuous), antihypertensive medication use (yes, no), plasma total and HDL-cholesterol (continuous), diabetes status (yes, no) and smoking status (never, ex-, or current smoke). As supplementary analyses, further adjustments for other cardiovascular risk factors, i.e. electrocardiographic left ventricular hypertrophy (yes, no), waist-hip ratio (continuous) and drinking status (non-current or current) were performed. In the CRS, unweighted Spearman correlation coefficients were computed for each hemostatic factor with systolic blood pressure, plasma total and HDL-cholesterol levels, waist-hip ratio, gender, race, diabetes, left ventricular hypertrophy, current smoker and current drinker. Adjusted R 2 values were calculated for multiple regression models containing each hemostatic factor as dependent variables and risk factors, age and antihypertensive medication use as the independent variables. All probability values for statistical tests were two-tailed and values of p 0.05 were regarded as statistically significant.
Results
As Table 1 shows, visit 2 systolic blood pressure, total cholesterol, diabetes and current smoker were higher among cases than the CRS. There was no difference in mean levels of hemostatic factors between cases and the CRS. To interpret these findings, we computed Spearman correlation coefficients of each hemostatic factor with classical risk factors ( Table 3) . As expected, each factor was correlated modestly with several classical risk factors. For example, factor was correlated with systolic blood pressure (r 0.15), with waist-hip ratio (r 0.13) and with diabetes (r 0.26). Factor was correlated with total cholesterol (r 0.14) and with diabetes (r 0.22). R 2 values for multiple regression models including the classical risk factors were 0.10 for factor , 0.11 for factor , 0.09 for factor , 0.08 for -2 antiplasmin and 0.16 for plasminogen. All of these factors were correlated with each other (r 0.14), and the correlation was especially strong between factors and (r 0.63).
Further adjustments for salicylates and hormone replacement therapy did not change the results (excluding 52 people missing hormone therapy). There were only 5 people who had used coumarin at the Visit 2 examination (4 among CHD cases and 1 in the CRS). Excluding these people did not affect the results. Similarly, when we excluded premenopausal women (n 17 excluded), the results were virtually unchanged (data Events include 25 people overlapping between the CRS and event groups. Model 1: adjusted for age, sex and race Model 2: further adjusted for systolic blood pressure, antihypertensive medication use, total and HDL-cholesterol, diabetes, and smoking status. Subjects with missing covariates were eliminated from model 2 analyses (14 eliminated). SD: standard deviation; CRS: cohort random sample; CHD coronary heart disease; HR: hazard ratio; CI: confidence interval not shown). Furthermore, when we used a hard endpoint (i.e., hospitalized myocardial infarction plus fatal CHD only) as the outcome (number of cases 218), these trends were similar; no significant association after multivariate adjustment.
Discussion
In this prospective study, factors and and -2 antiplasmin were associated positively with incident CHD, but these associations were non-significant after adjustments for classical coronary risk factors. The hemostatic factors were correlated with several classical risk factors, so the associations of these hemostatic factors with CHD were confounded by these risk factors. No significant association with incident CHD was observed for factor , , , or , or plasminogen across quartiles.
Few previous studies have examined the association between these hemostatic factors and incident CHD. In a nested case-control study of the Cardiovascular Health Study, no association was found between prothrombin (factor ) levels and incident or prevalent myocardial infarction 9) . Small case-control studies (n 22 to 300) have suggested that factors and were associated with CHD [10] [11] [12] , and factors , , and were not 10, 11) , generally consistent with our findings. No study had examined the association of factor or -2 antiplasmin activations with incident CHD in the general population to our knowledge. Factor activation peptide, factor a-C1 inhibitor, and factor -1-antitripsin complexes − markers of activation of factor or − have been reported to be associated with CHD 13, 14) . Taken together, the hemostatic factors examined here were not independently associated with incident CHD.
A prior case-cohort study in ARIC (follow-up from 1987 to 1993) 3) suggested that, although the association was nonlinear, a high level of plasminogen carried an elevated risk of incident CHD; HR 2.2 (1.2 − 4.2) for the highest vs lowest quintile. This was not replicated in the present study, due possibly to a large proportion of events later in follow-up (events occurring in the first year composed 9% in the present study compared with 19% in the prior ARIC report). The prior ARIC report suggested that the association for plasminogen was more prominent with early CHD events 3) . Our observations did not support the hypothesis that these factors are independently associated with increased risk of CHD. That is, the association of coagulation factors and and -2 antiplasmin with incident CHD, which we observed only in age, sex and race-adjusted models, seemed to reflect the association of these three factors with other classical risk factors for CHD. Thus, measuring these factors would have little impact for preventive cardiology, since it would add little benefit beyond classical risk factors in predicting CHD. Nevertheless, associations of factors and , and -2 antiplasmin found in the age, sex and race-adjusted model might reflect possible mechanistic roles in the pathogenesis of atherosclerosis.
Limitations of this study warrant discussion. First, the sample size was not large, although larger than most prior case-control studies. Given our CRS size (n 412), we could detect HR 1.6 between any two quartiles at 81% power. True associations weaker than HR 1.6, if any, may have been missed, but we did not find any estimates close to HR ≈ 1.6 between the highest and lowest quintiles; that is, all multivariable-adjusted associations were 1.27 or less. This would be a weak association whether it was statistically significant or not. Therefore, our conclusions may not be affected greatly by our sample size, although the results should be interpreted cautiously. Second, we split the original CRS into two parts to reduce measurement costs. This limited our statistical power, but we believe the process was statistically valid, because the splitting was done after random sorting of the sampling list. Third, it is possible that our findings were basically negative due to measurement error.
Having only a single measurement for each analyte may have obscured real associations. Also, the measurement repeatability was only modest for factors , , and and -2 antiplasmin. Moreover, although the samples were stored at 70 , we could not confirm the repeatability of measurements over the long sample preservation time (more than 10 years). Therefore, the null results presented here need to be confirmed by further studies.
In conclusion, higher levels of factors and , and -2 antiplasmin were associated with increased risk of CHD, but not independent of other coronary risk factors.
